Algernon Pharmaceuticals subsidiary completes first dosing in Phase 1 clinical study of DMT
News release
by
Algernon Pharmaceuticals Inc.
Vancouver
|
February 17, 2023 11:25 AM Eastern Standard Time
Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company’s subsidiary Algernon NeuroScience has announced it has completed the first dosing in its Phase 1 clinical study of an intravenous formulation of AP-188 or DMT.
Moreau told Proactive the safety review committee has approved moving the study forward with an escalated dose after observing no safety or tolerability issues. This study will include up to 60 healthy volunteers, including both psychedelic experienced and psychedelic naïve subjects.
Contact Details
Proactive Canada
+1 604-688-8158
